ATAI Life Sciences BV (ATAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ATAI Life Sciences BV (ATAI) has a cash flow conversion efficiency ratio of -0.106x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.09 Million) by net assets ($198.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ATAI company net worth for the company's overall valuation and market capitalisation.
ATAI Life Sciences BV - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how ATAI Life Sciences BV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ATAI Life Sciences BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ATAI Life Sciences BV ranked by their cash flow conversion efficiency. Explore ATAI Life Sciences BV (ATAI) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Autobio Diagnostics Co Ltd
SHG:603658
|
0.047x |
|
FRASERS PROPERTY
F:1IQ
|
N/A |
|
Bank Mega Tbk
JK:MEGA
|
0.624x |
|
Gold Road Resources Ltd
AU:GOR
|
0.122x |
|
HC Semitek Corp
SHE:300323
|
-0.016x |
|
Guangzhou Zhujiang Brewery Co Ltd
SHE:002461
|
0.053x |
|
Aerospace CH UAV Co Ltd
SHE:002389
|
-0.025x |
|
Turkiye Sigorta AS
IS:TURSG
|
0.034x |
Annual Cash Flow Conversion Efficiency for ATAI Life Sciences BV (2019–2025)
The table below shows the annual cash flow conversion efficiency of ATAI Life Sciences BV from 2019 to 2025. View ATAI Life Sciences BV (ATAI) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $222.00 Million | $-102.67 Million | -0.462x | +34.61% |
| 2024-12-31 | $116.55 Million | $-82.44 Million | -0.707x | -105.43% |
| 2023-12-31 | $244.32 Million | $-84.12 Million | -0.344x | +12.41% |
| 2022-12-31 | $265.77 Million | $-104.47 Million | -0.393x | -139.88% |
| 2021-12-31 | $385.96 Million | $-63.25 Million | -0.164x | +24.74% |
| 2020-12-31 | $95.37 Million | $-20.77 Million | -0.218x | -65.90% |
| 2019-12-31 | $59.78 Million | $-7.85 Million | -0.131x | -- |
About ATAI Life Sciences BV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more